Merck & Company
2000 Galloping Hill Road
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
3049 articles with Merck & Company
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
I-Mab Biopharma announced that it has entered into a clinical research collaboration agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of I-Mab's TJC4 and MSD's anti-PD-1 therapy, KEYTRUDA® in patients with multiple cancer types.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for PIFELTRO™
Merck had the unusual case of having its checkpoint inhibitor Keytruda (pembrolizumab) approved simultaneously in three countries for advanced endometrial carcinoma.
Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline
Themis well-funded through completion of Chikungunya Phase 3 program
9/18/2019The U.S. Food and Drug Administration approved Keytruda in combination with Eisai’s Lenvima for the treatment of patients with advanced endometrial carcinoma.
FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Merck and Eisai announced that the U.S. FDA approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available kinase inhibitor discovered by Eisai, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
9/16/2019September has been a relatively slow month for the U.S. Food and Drug Administration. However, there are two PDFUA dates remaining, although one of those took an unexpected turn that will delay it until later in the year.
Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1
Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer
Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities across the country to help end preventable maternal deaths
Merck announced new data from its broad oncology portfolio and pipeline will be presented at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain, from Sept. 27-Oct. 1, 2019.
Merck announced that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to present during a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on Sept. 9, 2019 at 10:30 a.m. EDT.
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta, a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma.
Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
Merck announced new data from the company’s leading clinical development program in lung cancer will be presented at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain from Sept. 7-10, 2019.
Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates
Themis Bioscience announced a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform.
8/21/2019Merck’s checkpoint inhibitor Keytruda (pembrolizumab) has been approved for 21 indications, but you’d better keep up, because it seems the drug is approved for some new indication or combination just about every week.